InvestSMART

Innate Immunotherapeutics Limited (ASX: IIL) - Announcements

Current share price for IIL : $0.360 0.02 (5.88%)+

ASX company news and announcements for Innate Immunotherapeutics Limited (IIL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Innate Immunotherapeutics Limited (IIL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Innate Immunotherapeutics Limited (IIL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Innate Immunotherapeutics Limited (IIL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Appendix 3B - Employee Options 27 Apr 2015 9:58AM $0.200 $0.360 risen by 80%
- Appendix 4C - Quarterly Cash Flow Report - Dec 14 Qtr 29 Jan 2015 10:30AM $0.195 $0.360 risen by 84.62%
- Patient Dosing Commences and Appointment of Dr Mansell 11 Nov 2014 8:46AM $0.195 $0.360 risen by 84.62%
- Appendix 4C - September 2014 Quarter 31 Oct 2014 11:06AM $0.195 $0.360 risen by 84.62%
- Update on Innate's Phase 2B trial and recent activities 7 Oct 2014 9:30AM $0.185 $0.360 risen by 94.59%
- Appendix 4C - June 2014 Quarterly Cash Flow Report 29 Jul 2014 10:16AM $0.180 $0.360 risen by 100%
- Update on Phase 2B Trial of MIS416 20 Jun 2014 8:28AM $0.170 $0.360 risen by 111.76%
- Compassionate Use Programme Update 18 Jun 2014 8:28AM $0.175 $0.360 risen by 105.71%
- Preliminary Final Report - Year Ended 31 March 2014 30 May 2014 9:55AM $0.180 $0.360 risen by 100%
- Appendix 4C - March 2014 Qtr Statement of Cash Flows 30 Apr 2014 8:25AM $0.180 $0.360 risen by 100%
- Phase 2B Trial on Track and on Budget 15 Apr 2014 11:55AM $0.210 $0.360 risen by 71.43%
- EU Radiation Patent 11 Mar 2014 10:45AM $0.300 $0.360 risen by 20%
- Response to ASX price and volume query 7 Mar 2014 8:22PM $0.280 $0.360 risen by 28.57%
- Newly Published MIS416 Therapy Validation in Animal Studies 3 Feb 2014 8:26AM $0.200 $0.360 risen by 80%
- Appendix 4C - Dec 2013 Quarterly Cash Flow Statement 31 Jan 2014 10:45AM $0.180 $0.360 risen by 100%
- Admission to Official List 19 Dec 2013 5:52PM n/a $0.360 n/a

176 - 191 of 191 results

Page 8 of 8

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.